Madrid
1 - 2
October
2026
Introduction and welcome
PART 1 | Myelofibrosis: what are new drugs contributing to clinical practice?
Dr. Valentín García Gutiérrez,
Hospital Universitario Ramón y Cajal. Madrid, Spain
Dr. Gilberto Barranco,
Hospital General de México. Mexico City
Dr. Carlos Plaza,
UEES Clinic y SOLCA. Guayaquil, Ecuador
Redefining the treatment algorithm for myelofibrosis
Dr. Blanca Xicoy,
ICO – Hospital Germans Trias i Pujol. Barcelona, Spain
The challenge of new treatments for myelofibrosis
Dr. Valentín García Gutiérrez,
Hospital Universitario Ramón y Cajal. Madrid, Spain
Targeting mutated CALR in myelofibrosis: from molecular biology to clinical application
Dr. Gonzalo Carreño,
Hospital Universitario 12 de Octubre. Madrid, Spain
Discussion
Coffee break
PART 2 | Low-Risk MDS
Dr. Ana Alfonso,
Clínica Universidad de Navarra. Pamplona, Spain
Dr. Isolda Fernández,
Centro de Hematología Pavlovsky. Buenos Aires, Argentina
Lower-risk MDS therapy: moving beyond quality of life toward overall survival
Dr. Guillermo García-Manero,
MD Anderson Cancer Center. Houston, USA
Discussion
Dr. Alessandro Isidori,
Marche Nord Hospital. Pesaro, Italy
Dr. Jordi Esteve,
Hospital Clínic de Barcelona, Spain
Dr. Joana Brioso Infante,
Centro Hospitalar Universitário de Lisboa Norte, Portugal
Cellular therapy platforms in acute myeloid leukemias: where are we now and where are we going?
Dr. Marion Subklewe,
Ludwig-Maximilians-Universität München, Germany
Is it time for CAR-T therapy in AML?
Dr. Nela Klein-González,
Hospital Clinic de Barcelona – IDIBAPS, Spain
Next generation CD19 CD3 bispecifics
Dr. Alba Puyuelo,
Hospital Universitario Vall d’Hebron. Barcelona, Spain
Pivekimab
Dr. Naval Daver,
MD Anderson Cancer Center. Houston, USA
Discussion
Lunch
Dr. Carlos Jiménez-Chillón,
Hospital General Universitario Gregorio Marañón, Madrid, Spain
Dr. Adolfo de la Fuente,
MD Anderson Cancer Center Madrid-Hospiten. Madrid, Spain
Dr. Mayte Olave,
Hospital Clínico Universitario Lozano Blesa. Zaragoza, Spain
Multidisciplinary Symposium on Systemic Mastocytosis: When complexity calls for a shared vision: a symposium among experts on diagnosis and management
Dr. David González de Olano,
Hospital Universitario Ramón y Cajal. Madrid, Spain
Dr. Miguel Piris-Villaespesa,
Hospital Universitario Ramón y Cajal. Madrid, Spain
Discussion
Dr. Ángela Figuera,
Hospital de La Princesa. Madrid, Spain
Dr. Adolfo de la Fuente,
MD Anderson Cancer Center Madrid-Hospiten, Spain
Dr. Joaquín Sánchez,
Hospital Universitario Reina Sofía. Córdoba, Spain
Hematologic neoplasms arising from donor cells
Dr. Andrés Jerez,
Hospital Universitario Vall d’Hebron. Barcelona, Spain
Clinical case
Late IDH1-mutated isolated extramedullary relapse in myelodysplasia-related acute myeloid leukemia secondary to primary myelofibrosis: triplet therapy followed by second allogeneic hematopoietic stem cell transplantation.
Dr. María Gaspar Regaño,
Hospital Clínico Universitario Lozano Blesa, Zaragoza
Discussion
Dr. Jordi Esteve,
Hospital Clínic de Barcelona, Spain
Dr. Anne Louise Tølbøll Sørensen,
Rigshospitalet Copenhagen University, Denmark
Dr. María Marta Rivas,
Hospital Universitario Austral. Buenos Aires, Argentina
The clue is in the details: the Paradigm study – design, patients and beyond
Dr. Alexander Perl,
Abramson Cancer Center – University of Pennsylvania. Philadelphia, USA
Intensive QT
Dr. Eduardo Rodríguez Arboli,
Hospital Universitario Virgen del Rocío. Sevilla, Spain
Ven+Aza
Dr. Irene Sánchez,
Hospital Universitario La Paz. Madrid, Spain
Discussion
Dr. Joaquín Sánchez,
Hospital Universitario Reina Sofía. Córdoba, Spain
Dr. Claudia Sossa,
Complejo Médico Fundación Oftalmológica de Santander – Clínica Carlos Ardila Lulle (FOSCAL). Bucaramanga, Colombia
Dr. Ana Alfonso,
Clínica Universidad de Navarra. Pamplona, Spain
Bone marrow inflammation in MDS: a driver of clonal evolution and a therapeutic opportunity?
Dr. José Miguel Torregrosa,
Poitiers University Hospital, France
Progress and future outlook in CMML
Dra. Blanca Xicoy,
ICO – Hospital Germans Trias i Pujol. Barcelona, Spain
Discussion
Coffee break
Dr. Margarida Coucelo,
Unidade Local de Saúde de Coimbra, Portugal
Dr. Claudia Núñez-Torrón,
Hospital Universitario Infanta Sofía. Madrid, Spain
Dr. María Marta Rivas,
Hospital Universitario Austral. Buenos Aires, Argentina
BIG picture biology and early phase studies
Dr. Adolfo de la Fuente,
MD Anderson Cancer Center Madrid-Hospiten, Spain
The challenge of testing: isocitrate dehydrogenase-1 testing and first-line treatment in patients with European Leukaemia Network-defined AML ineligible for intensive therapy: a multi-country survey
Dr. Alessandro Isidori,
Marche Nord Hospital. Pesaro, Italy
Ivosidenib and azacitidine for the treatment of adults with newly diagnosed acute myeloid leukemia (AML) who have an IDH1 gene mutation and are not eligible for intensive chemotherapy: the ALIDHE trial
Dr. Susana Vives Polo,
ICO – Hospital Universitario Germans Trias i Pujol. Barcelona, Spain
The impact of sequencing in AML
Dr. Rosa María Ayala,
Hospital Universitario 12 de Octubre. Madrid, Spain
Dr. Miguel López Esteban,
Hospital Universitario Gregorio Marañón. Madrid, Spain
Discussion
Dr. Mar Tormo,
Hospital Clínico Universitario de Valencia, Spain
Dr. Mónica Alejandra Romero,
Hospital Clínico Regional Dr. Guillermo Grant Benavente. Concepción, Chile
Dr. Virginia Abello,
Luis Carlos Sarmiento Angulo Cancer Treatment and Research Center. Bogotá, Colombia
New therapy for high-risk MDS in patients eligible for AloTPH
Dr. Marina Díaz,
Hospital Clínic de Barcelona, Spain
MRD in high-risk MDS: why we cannot simply copy the AML model
Dr. Guillermo García-Manero,
MD Anderson Cancer Center. Houston, USA
Discussion
